Kevin Balthaser - Net Worth and Insider Trading
Kevin Balthaser Net Worth
The estimated net worth of Kevin Balthaser is at least $33,550 dollars as of 2024-11-05. Kevin Balthaser is the CFO of Aclaris Therapeutics Inc and owns about 15,461 shares of Aclaris Therapeutics Inc (ACRS) stock worth over $33,550. Details can be seen in Kevin Balthaser's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Kevin Balthaser has not made any transactions after 2023-09-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Kevin Balthaser
Kevin Balthaser Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kevin Balthaser owns 1 companies in total, including Aclaris Therapeutics Inc (ACRS) .
Click here to see the complete history of Kevin Balthaser’s form 4 insider trades.
Insider Ownership Summary of Kevin Balthaser
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ACRS | Aclaris Therapeutics Inc | 2023-09-06 | Chief Financial Officer |
Kevin Balthaser Latest Holdings Summary
Kevin Balthaser currently owns a total of 1 stock. Kevin Balthaser owns 15,461 shares of Aclaris Therapeutics Inc (ACRS) as of September 6, 2023, with a value of $33,550.
Latest Holdings of Kevin Balthaser
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics Inc | 2023-09-06 | 15,461 | 2.17 | 33,550 |
Holding Weightings of Kevin Balthaser
Kevin Balthaser Form 4 Trading Tracker
According to the SEC Form 4 filings, Kevin Balthaser has made a total of 2 transactions in Aclaris Therapeutics Inc (ACRS) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Aclaris Therapeutics Inc is the acquisition of 9,490 shares on September 6, 2023, which cost Kevin Balthaser around $74,971.
Insider Trading History of Kevin Balthaser
- 1
Kevin Balthaser Trading Performance
GuruFocus tracks the stock performance after each of Kevin Balthaser's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kevin Balthaser is -86.49%. GuruFocus also compares Kevin Balthaser's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kevin Balthaser within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Kevin Balthaser's insider trading performs compared to the benchmark.
Performance of Kevin Balthaser
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -19.74 | | | | | |
| Relative Return to S&P 500(%) | -16.22 | | | | | |
Kevin Balthaser Ownership Network
Ownership Network List of Kevin Balthaser
Ownership Network Relation of Kevin Balthaser
Kevin Balthaser Owned Company Details
What does Aclaris Therapeutics Inc do?
Who are the key executives at Aclaris Therapeutics Inc?
Kevin Balthaser is the Chief Financial Officer of Aclaris Therapeutics Inc. Other key executives at Aclaris Therapeutics Inc include Chief Scientific Officer Joseph Monahan , Chief Business Officer James Loerop , and Pres and COO Douglas J. Manion .
Aclaris Therapeutics Inc (ACRS) Insider Trades Summary
Over the past 18 months, Kevin Balthaser made 1 insider transaction in Aclaris Therapeutics Inc (ACRS) with a net purchase of 9,490. Other recent insider transactions involving Aclaris Therapeutics Inc (ACRS) include a net purchase of 4,854,052 shares made by Braden Michael Leonard , a net sale of 18,000 shares made by Joseph Monahan , and a net purchase of 14,705 shares made by James Loerop .
In summary, during the past 3 months, insiders sold 0 shares of Aclaris Therapeutics Inc (ACRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 18,000 shares of Aclaris Therapeutics Inc (ACRS) were sold and 4,878,247 shares were bought by its insiders, resulting in a net purchase of 4,860,247 shares.
Aclaris Therapeutics Inc (ACRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aclaris Therapeutics Inc Insider Transactions
Kevin Balthaser Mailing Address
Above is the net worth, insider trading, and ownership report for Kevin Balthaser. You might contact Kevin Balthaser via mailing address: C/o Aclaris Therapeutics, Inc., 640 Lee Road, Suite 200, Wayne Pa 19087.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
